Our findings support the idea of using small molecule induce degradation of SYK as an alternative to SYK kinase inhibition, alone or combined with FLT3 inhibition for the treatment of AML characterised by FLT3-ITD and transformed by SYK. This evidence concerns the gene FLT3 and acute myeloid leukemia.